155 - From Evidence to Experience: Real-World Outcomes with Pembrolizumab in adults with untreated metastatic or unresectable recurrent HNSCC whose tumours express PD-L1 with a CPS of 1 or more.

Clinical Oncology · Published 2026-07-28 · DOI 10.1016/j.clon.2026.104135

Authors (2)

Tonia Soundaram, Pavithra Gayani

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Soundaram, T., Gayani, P. (2026). 155 - From Evidence to Experience: Real-World Outcomes with Pembrolizumab in adults with untreated metastatic or unresectable recurrent HNSCC whose tumours express PD-L1 with a CPS of 1 or more.. Clinical Oncology. https://doi.org/10.1016/j.clon.2026.104135

Related articles